Clinical Trial: Extended-Release RANCAD in the Patients With Stable Angina Pectoris

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Double-blind, Randomized, Placebo-controlled, Parallel Study to Evaluate the Effects of add-on RANCAD on Exercise Tolerance and Angina Frequency in Patients With Stable

Brief Summary: A double-blind, randomized, placebo-controlled, parallel study to evaluate the effects of add-on RANCAD on exercise tolerance and angina frequency in patients with stable angina pectoris.

Detailed Summary: Primary objective is to to determine the effects of add-on RANCAD on exercise treadmill test (ETT) duration at trough plasma level of RANCAD level after 12-weeks therapy.
Sponsor: TSH Biopharm Corporation Limited

Current Primary Outcome: ETT performing at last treatment visit (Week 12). [ Time Frame: Week 12 (not including screening & follow-up period) ]

To compare the change from baseline of ETT performing duration between add-on RANCAD and placebo at trough (12 hours after dosing) at Week 12.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: TSH Biopharm Corporation Limited

Dates:
Date Received: November 14, 2014
Date Started: October 2014
Date Completion:
Last Updated: April 26, 2017
Last Verified: April 2017